309 related articles for article (PubMed ID: 24095025)
1. Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer.
Howland NK; Driver TD; Sedrak MP; Wen X; Dong W; Hatch S; Eltorky MA; Chao C
J Surg Res; 2013 Dec; 185(2):697-703. PubMed ID: 24095025
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
3. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.
Carvalho FM; Bacchi LM; Pincerato KM; Van de Rijn M; Bacchi CE
BMC Womens Health; 2014 Aug; 14():102. PubMed ID: 25174527
[TBL] [Abstract][Full Text] [Related]
4. Descriptive analysis of molecular subtypes in Tunisian breast cancer.
Fourati A; Boussen H; El May MV; Goucha A; Dabbabi B; Gamoudi A; Sfar R; Rahal K; El May A; Ben Abdallah M
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e69-74. PubMed ID: 23176549
[TBL] [Abstract][Full Text] [Related]
5. Association between molecular subtypes and lymph node status in invasive breast cancer.
Si C; Jin Y; Wang H; Zou Q
Int J Clin Exp Pathol; 2014; 7(10):6800-6. PubMed ID: 25400761
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer recurrence according to molecular subtype.
Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer subtypes and the risk of local and regional relapse.
Voduc KD; Cheang MC; Tyldesley S; Gelmon K; Nielsen TO; Kennecke H
J Clin Oncol; 2010 Apr; 28(10):1684-91. PubMed ID: 20194857
[TBL] [Abstract][Full Text] [Related]
9. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
10. Can breast cancer molecular subtype help to select patients for preoperative MR imaging?
Grimm LJ; Johnson KS; Marcom PK; Baker JA; Soo MS
Radiology; 2015 Feb; 274(2):352-8. PubMed ID: 25325325
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.
Liu FF; Shi W; Done SJ; Miller N; Pintilie M; Voduc D; Nielsen TO; Nofech-Mozes S; Chang MC; Whelan TJ; Weir LM; Olivotto IA; McCready DR; Fyles AW
J Clin Oncol; 2015 Jun; 33(18):2035-40. PubMed ID: 25964246
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
14. Preoperative MRI Evaluation of Axillary Lymph Nodes in Invasive Ductal Carcinoma: Comparison of Luminal A Versus Luminal B Subtypes in a Paradigm Using Ki-67 and Receptor Status.
Plaza MJ; Handa P; Esserman LE
AJR Am J Roentgenol; 2017 Apr; 208(4):910-915. PubMed ID: 28140614
[TBL] [Abstract][Full Text] [Related]
15. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
18. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features of breast cancer with different molecular subtypes in Chinese women.
Cheng HT; Huang T; Wang W; Yue JQ; Shen N; Guo H; Li DP; Zhao QZ; Yi PF; Wang R; Wang LQ
J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):117-121. PubMed ID: 23392719
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
Tang P; Tse GM
Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]